620 related articles for article (PubMed ID: 29271940)
61. Mammalian target of rapamycin pathway promotes tumor-induced angiogenesis in adenoid cystic carcinoma: its suppression by isoliquiritigenin through dual activation of c-Jun NH2-terminal kinase and inhibition of extracellular signal-regulated kinase.
Sun ZJ; Chen G; Zhang W; Hu X; Huang CF; Wang YF; Jia J; Zhao YF
J Pharmacol Exp Ther; 2010 Aug; 334(2):500-12. PubMed ID: 20484154
[TBL] [Abstract][Full Text] [Related]
62. Metformin and Angiogenesis in Cancer - Revisited.
Kannarkatt J; Alkharabsheh O; Tokala H; Dimitrov NV
Oncology; 2016; 91(4):179-184. PubMed ID: 27487294
[TBL] [Abstract][Full Text] [Related]
63. The interaction of radiation therapy and antiangiogenic therapy.
O'Reilly MS
Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
[TBL] [Abstract][Full Text] [Related]
64. Hop derived flavonoid xanthohumol inhibits endothelial cell functions via AMPK activation.
Gallo C; Dallaglio K; Bassani B; Rossi T; Rossello A; Noonan DM; D'Uva G; Bruno A; Albini A
Oncotarget; 2016 Sep; 7(37):59917-59931. PubMed ID: 27494895
[TBL] [Abstract][Full Text] [Related]
65. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
66. The therapeutic potential of novel antiangiogenic therapies.
Scappaticci FA
Expert Opin Investig Drugs; 2003 Jun; 12(6):923-32. PubMed ID: 12783597
[TBL] [Abstract][Full Text] [Related]
67. Vascular endothelial growth factor as a target for antiangiogenic therapy.
Gordon MS
J Clin Oncol; 2000 Nov; 18(21 Suppl):45S-6S. PubMed ID: 11060326
[No Abstract] [Full Text] [Related]
68. Overview of angiogenesis: Biologic implications for antiangiogenic therapy.
Ellis LM; Liu W; Ahmad SA; Fan F; Jung YD; Shaheen RM; Reinmuth N
Semin Oncol; 2001 Oct; 28(5 Suppl 16):94-104. PubMed ID: 11706401
[TBL] [Abstract][Full Text] [Related]
69. Antiangiogenic agents and targets: A perspective.
Teicher BA
Biochem Pharmacol; 2011 Jan; 81(1):6-12. PubMed ID: 20920481
[TBL] [Abstract][Full Text] [Related]
70. Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.
Otrock ZK; Hatoum HA; Awada AH; Ishak RS; Shamseddine AI
Crit Rev Oncol Hematol; 2009 May; 70(2):93-102. PubMed ID: 19186072
[TBL] [Abstract][Full Text] [Related]
71. Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy.
Rey S; Schito L; Wouters BG; Eliasof S; Kerbel RS
Trends Cancer; 2017 Jul; 3(7):529-541. PubMed ID: 28718406
[TBL] [Abstract][Full Text] [Related]
72. Antiangiogenic agents in natural products for the treatment of gynecologic disorders.
Aghamohammadi A; Hosseinimehr SJ
Nutr Cancer; 2014; 66(2):206-13. PubMed ID: 24410431
[TBL] [Abstract][Full Text] [Related]
73. Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer.
Rajitha B; Nagaraju GP; Shaib WL; Alese OB; Snyder JP; Shoji M; Pattnaik S; Alam A; El-Rayes BF
Mol Carcinog; 2017 Jan; 56(1):288-299. PubMed ID: 27128654
[TBL] [Abstract][Full Text] [Related]
74. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug?
Cao Y
Int J Dev Biol; 2011; 55(4-5):557-62. PubMed ID: 21858776
[TBL] [Abstract][Full Text] [Related]
75. New Developments in Anti-Angiogenic Therapy of Cancer, Review and Update.
Ghasemali S; Farajnia S; Barzegar A; Rahmati-Yamchi M; Baghban R; Rahbarnia L; Nodeh HRY
Anticancer Agents Med Chem; 2021; 21(1):3-19. PubMed ID: 32807068
[TBL] [Abstract][Full Text] [Related]
76. Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice.
Lignet F; Benzekry S; Wilson S; Billy F; Saut O; Tod M; You B; Adda Berkane A; Kassour S; Wei MX; Grenier E; Ribba B
J Theor Biol; 2013 Mar; 320():86-99. PubMed ID: 23261980
[TBL] [Abstract][Full Text] [Related]
77. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
78. Metabolic effects of antiangiogenic drugs in tumors: therapeutic implications.
Quintieri L; Selmy M; Indraccolo S
Biochem Pharmacol; 2014 May; 89(2):162-70. PubMed ID: 24607274
[TBL] [Abstract][Full Text] [Related]
79. Angiogenesis as a therapeutic target.
Ferrara N; Kerbel RS
Nature; 2005 Dec; 438(7070):967-74. PubMed ID: 16355214
[TBL] [Abstract][Full Text] [Related]
80. Antiangiogenic peptides and proteins: from experimental tools to clinical drugs.
Rüegg C; Hasmim M; Lejeune FJ; Alghisi GC
Biochim Biophys Acta; 2006 Apr; 1765(2):155-77. PubMed ID: 16263219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]